LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models

Blood Cancer Discovery · Published 2026-07-23 · DOI 10.1158/2643-3230.bcd-25-0379

Authors (32)

Nathan A. Brooks, Anna Skwarska, Vivian Salama, Mark H. Bender, Lisa Kays, Robin I. DeWalt, Bryan Perria, Deepti Thete, Jason R. Manro, Rachel Cavitt, Rebecca Leon, Sandra Gomez, Raquel Torres, John M. Strelow, Paul Milligan, Kate Newell, Kenneth D. Roth, Jean-Emmanuel Sarry, Steven M. Chan, Danalyn Manglicmot Lagutan, Richard Romero, Stephen Antonysamy, Robert L. Johnson, Xueqian Gong, Renato A. Bauer, Timothy P. Burkholder, Patric J. Hahn, Zoran Rankovic, Serge L. Boulet, Courtney D. DiNardo, Marina Konopleva, Raymond Gilmour

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Brooks, N., Skwarska, A., Salama, V., et al. (2026). LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models. Blood Cancer Discovery. https://doi.org/10.1158/2643-3230.bcd-25-0379

Related articles

• Improving Knowledge and Care of Patients with AML: The Need to Get Out of Our Comfort Zone · Blood Cancer Discovery · 2026 · Same journal
• MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1 -Mutant Leukemia · Blood Cancer Discovery · 2026 · Same journal
• Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry · Blood Cancer Discovery · 2026 · Same journal
• Rewiring the Leukemic Genome: 3D Chromatin Architecture in B-cell Acute Lymphoblastic Leukemia · Blood Cancer Discovery · 2026 · Same journal
• The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells · Blood Cancer Discovery · 2026 · Same journal
• Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies · Blood Cancer Discovery · 2026 · Same journal
• Highlighted Research Articles · Blood Cancer Discovery · 2026 · Same journal
• Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma · Blood Cancer Discovery · 2026 · Same journal
• Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial · Blood Cancer Discovery · 2026 · Same journal
• A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma · Blood Cancer Discovery · 2026 · Same journal